
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Aldolase C CRISPR/Cas9 KO Plasmid (h) | sc-400988 | 20 µg | $397.00 |
ALDOC encodes aldolase C, a fructose-bisphosphate aldolase isozyme that catalyzes a key reversible step in glycolysis and gluconeogenesis, converting fructose 1,6-bisphosphate into glyceraldehyde 3-phosphate and dihydroxyacetone phosphate. In human tissues, ALDOC is enriched in the central nervous system and contributes to neuronal energy metabolism, coupling glycolytic flux to redox balance and biosynthetic demands. Beyond its metabolic role, aldolase C has been linked to regulation of cytoskeletal organization and cellular stress responses through metabolite-sensitive signaling networks. Altered ALDOC expression or activity is frequently studied in the context of neurologic vulnerability and metabolic reprogramming observed across diverse disease states, providing a mechanistic entry point for pathway interrogation in cell and tissue models.
Aldolase C CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ALDOC gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ALDOC together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ALDOC open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Aldolase C protein expression.
This CRISPR knockout system enables efficient generation of ALDOC-deficient cell models for investigation of Aldolase C signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.